— Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 — — Reaffirms Year-End 2023 Cash Position of $321 Million and Full-Year Positive Cash Flow of $10 Million — — Company […]
Tag: Amarin
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss its […]
Amarin Chairman & CEO Issue Letter to Shareholders
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Chairman of the Board, Odysseas Kostas, M.D., and President & CEO, Patrick Holt, issued the following letter to Amarin shareholders: […]
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
— Reported Unaudited Total Revenues of Between $72 Million – $74 Million in the Fourth Quarter of 2023 — — Company Ends 2023 with a Cash Position of $321 Million and Delivered Full-Year Positive Cash Flow of ~$10 Million — […]
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
— Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo — — Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease — — Findings Continue to Reinforce the Scientific Data and Clinical […]
AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023
New Repatha® (evolocumab) Data Show No Decline in Cognitive Function Associated With Very Low Levels of LDL-C Olpasiran Research Provides Further Insights Into Cardiovascular Risks Associated With Elevated Lp(a) Amgen Provides Updates on Efforts to Advance Bold Ambition of Halving the…
Amarin Reports Third Quarter 2023 Financial Results
— Company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 — — Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecutive Quarter of Cash Positive Operations1; Quarter-Ending Cash Position of $321 Million […]
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal and; Compliance Officer
— Provoost Brings More than 20 Years of Corporate Counsel Experience to Amarin — DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Jonathan Provoost as the Company’s new […]
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
DUBLIN, Ireland and BRIDGEWATER, N.J. and NANTOU, Taiwan, July 31, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) and Lotus Pharmaceuticals (1795:TT; “Lotus”) today announced that the two companies have entered into a long-term exclusive partnership to distribute and commercialize […]
Amarin Appoints Patrick Holt as President and Chief Executive Officer
DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company’s Board of Directors has appointed Patrick Holt as President and Chief Executive Officer and as a member of the […]
Recent
BrioHealth Solutions Begins Patient Enrollment in INNOVATE Trial of BrioVAD® System for Advanced Heart Failure
Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data
Popular
- No commented posts yet